Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2073

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2073
---
PI-based therapies.

A
general overview of immunotherapy and antibodies is presented below under the caption “A Primer on Antibodies, Antigens and Targeted
Therapies.”

18

We
believe that OCX-253, our mono-specific mAb against Chi3l1, if approved, will likely be used individually or in combination with immunotherapies,
such as anti-PD-1 therapeutics. Our belief is based on the observation that OCX-253 modulates multiple oncogenic pathways, or signaling
networks used by cancer cells to control the growth and progression of tumors, in addition to its ability to modulate ICPI pathways.
Should OCX-253 become a marketed treatment, we would anticipate it being initially used primarily in later-stage cancers, as with most
recently approved oncology therapeutics. OCX-253 may progress towards being used for earlier stage cancers, and/or in combination with
other medications, as clinician and regulatory agency experience with the drug grows and as our understanding of the needs of individual
patients deepens.

OCX-410,
our bi-specific antibody, is designed to combine the mechanism of actions of OCX-253 and anti-PD-1 therapeutics. We believe this is a
promising combination because studies by Dr. Elias have demonstrated that this bi-specific antibody recruits immune cells, such as CD8+
cytotoxic T cells that kill tumor cells, and the physical interaction of these activated T cells to tumor cell membranes. If approved,
we anticipate that OCX-410 will likely enter the market as a second-line therapy in patients with stage III or IV lung cancer who have
failed anti PD-1/PD-L1 immunotherapies. We believe that OCX-410 may eventually be used as a first-line treatment for patients with later
stage NSCLC.

Glioblastoma
Multiforme

GBM
is an aggressive type of cancer that can occur in the brain or spinal cord, the components of the central nervous system, or CNS, and
is the most common brain tumor in adults. GBMs are a type of astrocytoma, meaning that they arise from the star-shaped cells, known as
astrocytes, in the CNS. Normally, these cells form a key component of the blood brain barrier, or BBB, a network of cells, proteins,
and structural components that controls which substances can get into the central nervous system, or CNS, and which cannot. Astrocytes